143 related articles for article (PubMed ID: 24386452)
1. 9G4+ antibodies isolated from HIV-infected patients neutralize HIV-1 and have distinct autoreactivity profiles.
Alcéna DC; Kobie JJ; Kaminski DA; Rosenberg AF; Mattiacio JL; Brewer M; Dewhurst S; Dykes C; Jin X; Keefer MC; Sanz I
PLoS One; 2013; 8(12):e85098. PubMed ID: 24386452
[TBL] [Abstract][Full Text] [Related]
2. 9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity.
Kobie JJ; Alcena DC; Zheng B; Bryk P; Mattiacio JL; Brewer M; Labranche C; Young FM; Dewhurst S; Montefiori DC; Rosenberg AF; Feng C; Jin X; Keefer MC; Sanz I
PLoS One; 2012; 7(4):e35356. PubMed ID: 22530008
[TBL] [Abstract][Full Text] [Related]
3. 9G4+ autoantibodies are an important source of apoptotic cell reactivity associated with high levels of disease activity in systemic lupus erythematosus.
Jenks SA; Palmer EM; Marin EY; Hartson L; Chida AS; Richardson C; Sanz I
Arthritis Rheum; 2013 Dec; 65(12):3165-75. PubMed ID: 23983101
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis of 9G4 B cell autoreactivity in human systemic lupus erythematosus.
Richardson C; Chida AS; Adlowitz D; Silver L; Fox E; Jenks SA; Palmer E; Wang Y; Heimburg-Molinaro J; Li QZ; Mohan C; Cummings R; Tipton C; Sanz I
J Immunol; 2013 Nov; 191(10):4926-39. PubMed ID: 24108696
[TBL] [Abstract][Full Text] [Related]
5. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
McGuire AT; Glenn JA; Lippy A; Stamatatos L
J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
[TBL] [Abstract][Full Text] [Related]
6. An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1.
Bonsignori M; Wiehe K; Grimm SK; Lynch R; Yang G; Kozink DM; Perrin F; Cooper AJ; Hwang KK; Chen X; Liu M; McKee K; Parks RJ; Eudailey J; Wang M; Clowse M; Criscione-Schreiber LG; Moody MA; Ackerman ME; Boyd SD; Gao F; Kelsoe G; Verkoczy L; Tomaras GD; Liao HX; Kepler TB; Montefiori DC; Mascola JR; Haynes BF
J Clin Invest; 2014 Apr; 124(4):1835-43. PubMed ID: 24614107
[TBL] [Abstract][Full Text] [Related]
7. Will studies in individuals with systemic lupus erythematosus be the key to future HIV vaccine design?
Bonsignori M
Expert Rev Vaccines; 2014 Nov; 13(11):1271-3. PubMed ID: 25017952
[TBL] [Abstract][Full Text] [Related]
8. Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject.
Mikell I; Stamatatos L
PLoS One; 2012; 7(11):e49610. PubMed ID: 23152926
[TBL] [Abstract][Full Text] [Related]
9. VH4-34 encoded antibody in systemic lupus erythematosus: effect of isotype.
Bhat NM; Lee LM; van Vollenhoven RF; Teng NN; Bieber MM
J Rheumatol; 2002 Oct; 29(10):2114-21. PubMed ID: 12375320
[TBL] [Abstract][Full Text] [Related]
10. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10.
Chen Y; Zhang J; Hwang KK; Bouton-Verville H; Xia SM; Newman A; Ouyang YB; Haynes BF; Verkoczy L
J Immunol; 2013 Aug; 191(3):1260-75. PubMed ID: 23825311
[TBL] [Abstract][Full Text] [Related]
11. Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations.
Hicar MD; Chen X; Kalams SA; Sojar H; Landucci G; Forthal DN; Spearman P; Crowe JE
Mol Immunol; 2016 Feb; 70():94-103. PubMed ID: 26748387
[TBL] [Abstract][Full Text] [Related]
12. Histone H2A-Reactive B Cells Are Functionally Anergic in Healthy Mice With Potential to Provide Humoral Protection Against HIV-1.
Agazio A; Cimons J; Shotts KM; Guo K; Santiago ML; Pelanda R; Torres RM
Front Immunol; 2020; 11():1565. PubMed ID: 32849530
[TBL] [Abstract][Full Text] [Related]
13. B cell clonal lineage alterations upon recombinant HIV-1 envelope immunization of rhesus macaques.
Yacoob C; Lange MD; Cohen K; Lathia K; Feng J; Glenn J; Carbonetti S; Oliver B; Vigdorovich V; Sather DN; Stamatatos L
PLoS Pathog; 2018 Jun; 14(6):e1007120. PubMed ID: 29933399
[TBL] [Abstract][Full Text] [Related]
14. Failure of B Cell Tolerance in CVID.
Richardson CT; Slack MA; Dhillon G; Marcus CZ; Barnard J; Palanichamy A; Sanz I; Looney RJ; Anolik JH
Front Immunol; 2019; 10():2881. PubMed ID: 31921145
[TBL] [Abstract][Full Text] [Related]
15. Polyreactive Antibodies in Anti-HIV-1 Responses.
Liao H; Zhang Z
Curr Mol Med; 2018; 18(2):126-133. PubMed ID: 30033868
[TBL] [Abstract][Full Text] [Related]
16. Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein.
Hicar MD; Chen X; Sulli C; Barnes T; Goodman J; Sojar H; Briney B; Willis J; Chukwuma VU; Kalams SA; Doranz BJ; Spearman P; Crowe JE
PLoS One; 2016; 11(7):e0158861. PubMed ID: 27411063
[TBL] [Abstract][Full Text] [Related]
17. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
18. Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses.
Verkoczy L; Chen Y; Zhang J; Bouton-Verville H; Newman A; Lockwood B; Scearce RM; Montefiori DC; Dennison SM; Xia SM; Hwang KK; Liao HX; Alam SM; Haynes BF
J Immunol; 2013 Sep; 191(5):2538-50. PubMed ID: 23918977
[TBL] [Abstract][Full Text] [Related]
19. Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.
Sajadi MM; Lewis GK; Seaman MS; Guan Y; Redfield RR; DeVico AL
J Virol; 2012 May; 86(9):5014-25. PubMed ID: 22379105
[TBL] [Abstract][Full Text] [Related]
20. Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design.
Finney J; Kelsoe G
Retrovirology; 2018 Jul; 15(1):53. PubMed ID: 30055635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
